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PURPOSE. The ‘‘high-risk phenotype’’ of corneal graft recipients is considered to be related to
preexisting vascularization such as that associated with herpes simplex virus-1 (HSV-1)
keratitis (HSK). The purpose of this study was to investigate the immunologic mechanisms
underlying accelerated corneal graft rejection using a mouse model of HSK.
METHODS. Herpes simplex virus type 1 keratitis was induced in BALB/c mice. Syngeneic and
allogeneic (C57BL/6 mice) corneal grafts were performed in mice with HSK at different times
after infection. Some grafts were performed on HSV-infected CD4 T cell–deficient BALB/c
mice. Clinical, histologic, immunologic, and virus detection studies were performed on
samples of cornea, draining lymph node (LN), and trigeminal ganglion (TG) cells.
RESULTS. Corneal grafts in mice with HSK rejected with higher frequency and more rapid
tempo compared with grafts in uninfected mice. In corneas with HSK and vascularization at
the time of grafting, both syngeneic and allogeneic corneal grafts failed with similar frequency
and tempo. However, in the absence of preexisting inflammation and vascularization,
syngeneic grafts were accepted when the grafts were performed at a late time point after HSV
infection (42 days), whereas allografts were rejected at this time. In contrast, syngeneic grafts
in nonvascularized HSV-infected recipients failed if they were performed within 10 days of HSV
infection, an effect that was dependent on CD4 T cells, as demonstrated using CD4 deficient
mice. Importantly, a variably sustained but strongly positive anti-HSV T-cell response was
detected in allografted HSK recipients with a similar but lesser response in syngeneic hosts.
CONCLUSIONS. A previous HSV-1 corneal infection predisposes donor grafts to a high risk of
failure by both innate and adaptive immune mechanisms in which an anti-HSV CD4 T-cell
response plays a prominent role.
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Blindness due to corneal infectious disease is a majorworldwide problem and herpes stromal keratitis (HSK)
contributes to this morbidity in large measure.1,2 Herpes
stromal keratitis is a recurrent disease initiated after mucosal
infection with herpes simplex virus type 1 (HSV-1) often in
early childhood followed by spread to the trigeminal ganglion
(TG), where HSV-1 resides in a latent state. Latent HSV-1 reverts
to a replicative cycle in response to environmental and
physiological stimuli such as stress, exposure to ultraviolet
light, and altered levels of sex hormones.3,4 Reactivation of
HSV-1 in TG neurons results in anterograde transport of virus to
the cornea and recurrent bouts of HSK. Progressive visual
impairment associated with recurrent nonnecrotizing HSK
results from development of scar tissue in the cornea.5
Treatment of corneal opacification due to HSK is to replace
the opaque cornea with a clear donor corneal graft. However,
recipients of such grafts are considered ‘‘high-risk’’ as the grafts
frequently fail.6,7 This high-risk phenotype is attributed to
extensive corneal vascularization and leukocytic infiltration
associated with HSK.8 Indeed, recent clinical studies confirm
that HSK patients with apparently ‘‘quiescent’’ eyes have a high
risk of graft rejection for these reasons.9 However, a direct
cytotoxic effect of reactivated HSV on donor graft cells is also a
suggested mechanism for graft rejection. Indeed, severing of
latently infected TG neurons/nerve endings during excision of
the host cornea is considered a sufficient stimulus to induce
HSV-1 reactivation with anterograde virus transport to the graft
site resulting either in direct viral damage or indirect damage
due to an antigen-specific T-cell recall response.10–12 Human
clinical studies have shown HSV-1 DNA as well as virus particles
in host corneas, in donor-rejected corneas, and in aqueous
samples from patients with rejecting corneal grafts,13 and has
led to the common practice of antiviral prophylaxis as part of
the management of HSK patients. Experimental studies in
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rabbits have also shown an increase in viral shedding in tear
fluid after lamellar corneal grafts with some epithelial lesions
but without development of HSK.14,15 In contrast, no
correlation between virus shedding after grafting and allograft
rejection in rats was found.16
Determining the precise role of HSV-1 in graft rejection after
corneal transplantation for HSK is important both clinically and
biologically. The clinical importance is self-evident, while the
biological importance relates to whether viral reactivation or the
associated induced anti-viral immune response mediates graft
rejection. Allograft rejection in high-risk grafts generally is
associated with preexisting corneal blood and lymphatic vessels
and is mediated by alloreactive CD4þ T cells.17 In the
conventional experimental model of high-risk corneal graft
rejection, sutures inserted into the cornea induce inflammation
and vascularization prior to grafting, and accelerate allograft
rejection, but not syngraft, with rejection frequencies approach-
ing 100%.18,19 More recently, we have described a high-risk
corneal regraft model in which there is also allospecific
accelerated graft rejection.20,21
In the current study, we report a further high-risk corneal
allograft model using HSK as the host. We find that accelerated




For studies performed in the United States, female wild-type
(WT) and CD4þ T cell–deficient BALB/c (CD4/) mice were
bred in an Association for Assessment and Accreditation of
Laboratory Animal Care-accredited University of Pittsburgh
(Pittsburgh, PA, USA) animal facility and used as corneal
transplant recipients. Wild-type BALB/c (H-2d; Jackson Labora-
tory, Bar Harbor, ME, USA) and C57BL/6J (H-2b; Jackson
Laboratory) mice served as syngeneic and allogeneic corneal
donors, respectively. All animal studies were approved by and
conducted in accordance with the University of Pittsburgh
Institutional Animal Care and Use Committee.
For studies performed in Scotland, mice were bred and
housed in the UK Home Office accredited Medical Research
Facility of the University of Aberdeen (Aberdeen, Scotland,
UK). Wild-type donor (C57BL/6J) and recipient (BALB/c) pairs
were used as described above. An additional group of animals
was treated with systemic Acyclovir (ACV) at a dose of 10 mg/
kg body weight in the drinking water. All animal studies were
performed in accordance with guidelines described in the
ARVO Statement for the Use of Animals in Vision and
Ophthalmic Research and Animal License Act (UK).
Orthotopic Corneal Transplantation
A central 1.5 mm of the host cornea was trephined and the
corneal button secured to the host bed using eight interrupted
11-0 nylon sutures (Pittsburgh) or one continuous suture
(Aberdeen) as described previously.22
Corneal HSV-1 Infection
Six- to 10-week-old female WT or CD4/ BALB/c were
anesthetized, the corneas scarified with a sterile 30-G needle
and 3 lL of RPMI containing 1 3 105 pfu of the RE strain of
HSV-1 applied as previously described.23 Wild-type and CD4/
mice were infected for more than 30 and 10 days, respectively,
prior to transplantation.
CD4 T-Cell Isolation and Adoptive Transfer
CD4 T cells were isolated from spleens of WT BALB/c mice by
negative selection using EasySep Mouse CD4þ T Cell Enrich-
ment Kit (StemCell Technologies, Vancouver, BC, Canada).
Purification was assessed by flow cytometry and was greater
than 90% in all experiments. Where indicated, 2.5 3 106
isolated cells in 200-lL sterile Hanks’ balanced salt solution
(HBSS) were transferred per mouse via tail vein injection.
Tissue Retrieval and Preparation for
Immunohistochemistry
Mice were killed with an overdose of CO2, the eyes were
immediately immersed in OCT medium, snap frozen in cooled
isopentane on dry ice, and stored at 808C until used. Primary
antibody was placed for 1 hour at room temperature on 6-lm
thick eye sections, followed by secondary biotinylated rabbit anti-
rat (DakoCytomation, Glostrup, Denmark) or biotinylated mouse
anti-hamster Ig cocktail (BD Pharmingen, Oxford, UK) for 30
minutes at room temperature followed by Vectastain ABC-AP kit
(Vector Laboratories, Peterborough, UK) for 30 minutes. For
confocal imaging secondary fluorescent-labelled antibodies Alexa
Fluor 555 goat anti-rat IgG (Invitrogen, Waltham, MA, USA) and
Alexa Fluor 488 goat anti-rat IgG (Invitrogen) were used together
with nuclear staining 40,6-diamidino-2-phenylindole (DAPI, Vector
Laboratories, Peterborough, UK). The following primary mono-
clonal antibodies (mAb) were used in concentrations as suggested
by the manufacturer: rat anti-mouse CD11b (clone M1/70); rat
anti-mouse CD4 (clone H129.19), rat anti-mouse CD8a (clone 53-
6.7), rat anti-mouse Gr-1 (clone RB6-8C5), hamster anti-mouse
CD11c (clone HL3; all from BD Pharmingen) and rat anti–mouse
F4/80 (clone C1:A3-1; AbD Serotec, Kidlington, UK).
Preparation of Corneal Whole Mounts
Corneas were excised, washed in PBS with 4% fetal bovine serum
(FBS) for 10 minutes at 48C prior to fixation in CytoFix/
CytoPerm24 for 1 hour at 48C. The tissue was washed three times
in PBS with 4% FBS prior to incubation with primary
fluorochrome-conjugated antibodies overnight at 48C. Following
three washes, the tissue was mounted in Immu-Mount (Thermo
Scientific, Waltham, MA, USA) or Vectashield Mounting Medium
(Vector Laboratories, Burlingame, CA, USA) with DAPI (Vector
Laboratories, Burlingame, CA, USA) prior to confocal imaging.
Antibodies used were Pacific Blue-conjugated anti-CD4 (BD;
clone: RM4-5), Pacific Blue- or allophycocyanin-(APC)-conjugated
anti-CD11b (eBioscience; clone: M1/70), APC-conjugated anti-
MHC class II (I-A/I-E; clone: M5/114.15.2; eBioscience, San Diego,
CA, USA).
Confocal Imaging of Corneal Whole Mounts
Images were acquired by sequential scanning to avoid
fluorescence crossover on an Olympus Fluoview 31000
confocal microscope (Center Valley, PA, USA). Z stacks through
the tissue were acquired at Nyquist sampling frequency. All
image reconstructions were made using MetaMorph (version:
7.5.4.0; Molecular Devices, Sunnyvale, CA, USA).
Detection of HSV-1 DNA in Transplanted Corneas
and TG
Corneal buttons and TGwere removed at the specific time points
after corneal allografting and snap frozen in liquid nitrogen. DNA
was extracted with Dneasy blood and tissue kit (Qiagen,
Manchester, UK) and quantified with NanoDrop 1000 spectro-
photometer (Thermo Scientific). Twenty-five nanograms DNA or
control water only was mixed in TaqMan PCR Master Mix
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(Applied Biosystems, Thermo Scientific,Waltham, MA, USA)with
anHSV-1 glycoprotein H (gH)-specific primer. Final PCRproducts
were detected on ethidium bromide-stained agarose gel.
Proliferation Assay
Ipsilateral eye draining (submandibular) LN (DLN) were identified
and removed at different times after infection of the cornea with
HSV-1 (see above). As a control we used inguinal, non-eye DLN. In a
preliminary analysis, samples from nongrafted mice were analyzed
for HSV-1 DNA at various times up 42 days post infection (dpi).
Samples harvested from grafted mice were taken 42 dpi plus 7 days
post graft (i.e., 49 days in total post infection) and were compared
with positive control samples taken from nongrafted HSV-1–
infected mice 5 dpi and tested in the same assay. Lymphocytes
were seeded (1.53104 cells/well) into 96-well plates in triplicates
and stimulated with B6 antigen (lysate of splenocytes from C57BL/
6 mice; 6 lg/well) or with HSV-1 protein (lysate of infected VERO
cells; 6 lg/well) with appropriate controls. Cells were cultured for
96 hours, last 16 hours spiked with [H3]thymidine.
Statistics
For statistical analysis a log-rank test (Mantel-Cox) was used for
comparing survival curves (GraphPad Prism Software, Inc.,
version 5.04, La Jolla, CA, USA). A P value of less than 0.05 was
considered significant.
RESULTS
Survival of Corneal Grafts in BALB/c Mice With
Latent HSV-1 Infections
Herpes simplex virus-1 applied to scarified BALB/c mouse
corneas produces an initial dendritic/geographic lesion that
heals around 3 dpi, with clearance of infectious virus by 6 to 8
dpi.23 Most of the mice (80%–90%), over the next 2 to 3 weeks,
develop chronic HSK with vascularization and variable
ulceration. Ten percent to 20% mice clear the virus without
inflammatory sequelae and have clear nonvascularized cor-
neas. To determine acceptance rates, allografts were per-
formed in chronically HSV-infected (6 weeks post infection)
WT BALB/c mice, 80% to 90% of which had HSK grade 2 to 3 or
above (Fig. 1a). All grafts in active HSK recipients failed (onset
3 days, maximal 15 days post grafting; Fig. 1b). Survival curves
of previously infected recipients (allo-HSK or syn-HSK) were
compared with noninfected allografts (allo) and showed some
striking differences with P values as follows: allo-HSK versus
allo, P less than 0.0001; allo-HSK versus syn-HSK, P ¼ 0.9053.
Failed grafts showed extensive vascularization with stromal
opacification (see Fig. 1c). Interestingly, in recipients with
severe HSK and 3608 vascularization, syngeneic grafts failed as
rapidly as allografts (Fig. 1b). Acyclovir is a widely used anti–
HSV-1 medication. We therefore assessed the effect of ACV
therapy on the survival of corneal allografts in HSV-infected
recipients. Herpes simplex virus–infected animals were treated
with ACV (10 mg/kg) in the drinking water immediately after
surgical procedure for the duration of the study. The survival of
allografts was not different from the survival of allografts in
HSV-infected, untreated animals (Fig. 1b; allo-HSK versus allo-
HSKþACV P ¼ 0.6692; allo-HSKþACV versus allo P ¼ 0.0002).
In contrast, HSV-infected allogeneic grafts, where the inflam-
mation had subsided and the cornea was clear without
vascularization at the time of grafting, underwent accelerated
graft rejection (Fig.1d; nonvascularized corneal graft bed: allo-
HSK versus syn-HSK, P ¼ 0.0012; allo-HSK versus allo P ¼
0.2285; syn-HSK versus allo P ¼ 0.0356).
Endothelial cell loss is the main cause of graft failure22 and
may result from immune (allograft) or nonimmune (allograft
and syngraft) damage. The above results suggested that failure
FIGURE 1. Rejection of corneal grafts placed into WT HSV-1–infected high-risk hosts. Wild-type BALB/c mice were infected with HSV-1 6 weeks (42
days) prior to placement of corneal grafts, which were secured with a continuous suture in this set of experiments. (a) Clinical appearance of the
vascularized corneal graft bed at 6 week post HSV-1 infection; (b) corneal graft survival in vascularized corneal beds in syngraft HSK (n ¼ 15),
allograft HSK (n¼ 20), and allograft HSK treated with ACV (n¼ 10) groups compared with WT, noninfected BALB/c recipients transplanted with
allograft (n¼ 20); (c) clinical appearance of rejecting corneal allograft placed into vascularized corneal graft bed (day 3 post allograft); (d) corneal
graft survival in previously infected but not vascularized (at 6 weeks post infection [p.i.]) graft beds for both allo- and syngrafts compared with WT,
noninfected BALB/c recipient transplanted with allograft.
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of both syngeneic and allogeneic grafts following HSV infection
may have been due to innate (HSV-induced inflammation)
rather than adaptive (allo) immunity. We hypothesized
therefore that allografts, but not syngrafts, in HSK recipients
would fail through alloimmune damage only if the grafts were
performed before HSV-induced inflammation/neovasculariza-
tion (i.e., clinically overt HSK) occurred. We therefore
performed grafts in HSV-infected corneas before they devel-
oped overt HSK (i.e., 10 dpi) when the corneas were still clear
and had no vascularization. However, when the grafts were
performed in HSV-infected recipients, both syn- and allo-grafts
rapidly failed (P ¼ 0.1211; Fig. 2a). We then assessed the
contribution of adaptive immunity (specifically the CD4 T-cell
response) directly by performing grafts in HSV infected CD4/
mice, which do not develop significant inflammation or
vascularization following HSV-1 corneal infection but do
establish a latent infection in the TG by 10 dpi.23 As shown
in Figure 2b, only approximately 25% of infected CD4/ BALB/c
mice developed graft failure, while 100% of infected CD4/
BALB/c mice that were adoptively transferred with na¨ıve WT
CD4 T cells, rejected their allografts by 14 days post graft. In
contrast, only 20% of syngrafts in CD4/ mice failed after
adoptive transfer of na¨ıve WT CD4þ T cells, which was not
significantly different from the 100% acceptance of syngeneic
grafts in nonreconstituted mice (Fig. 2c).
The clinical findings were also evaluated by immunohisto-
chemistry. Data in Figure 3 confirm the lack of blood or
lymphatic vessels in HSV-1–infected corneas of CD4/mice 10
dpi as well as in HSV-infected corneas of CD4/ mice after
grafting. However, allografted corneas from mice that received
CD4þ T cells at the time of grafting had extensive blood and
lymphatic vessel ingrowth into both the graft bed and the
rejecting graft (Figs. 3A, 3B). Thus, while HSK-associated high-
risk graft failure is accompanied by an ingrowth of blood and
lymphatic vessels, preexisting vessels did not directly influence
either the frequency or tempo of allograft rejection.
FIGURE 2. Rejection of corneal grafts placed into HSV-1–infected low-
risk hosts. (a) Wild-type BALB/c mice were infected with HSV-1 and
corneal grafts were performed 10 dpi (grafts secured with continuous
suture) when corneas typically do not have corneal neovascularization
or corneal scar. (b, c) CD4/ BALB/c mice were infected with HSV-1
for 10 days prior to placement of corneal allografts (grafts secured with
interrupted sutures; [b] C57BL/6J donors) or syngrafts (grafts secured
with interrupted sutures; [c] WT BALB/c donors). Mice received 2 3
106 na¨ıve WT BALB/c CD4 T cells intravenously (with CD4s) at the
time of transplant or not (no CD4s), and grafts were monitored for
rejection at various times post transplant.
FIGURE 3. Infiltration of blood and lymph vessels as well as antigen-
presenting cells into transplanted corneas. Corneas from the indicated
mice at the indicated times were excised, stained for lymph vessels
(LYVE-1; green), blood vessels (CD31; red), and MHC class IIþ cells
(blue), and imaged by confocal microscopy. (A) Representative
montages acquired via wide-field microscopy of a nongrafted CD4/
cornea obtained 10 days after HSV-1 corneal infection (top), CD4/
cornea infected with HSV-1 10 days prior to corneal allotransplantation
and adoptive transfer of na¨ıve WT BALB/c CD4 T cells (middle), and
CD4/ cornea infected 10 days prior to corneal allograft without
receiving CD4 T cells (bottom; all above results generated from grafts
secured with interrupted sutures). (B) High magnification images (Left:
xy; Right: xz) of a cornea from a CD4/mouse infected with HSV-1 10
days prior to corneal allotransplantation and adoptive transfer of na¨ıve
WT BALB/c CD4 T cells ([A], middle panel).
High Risk Recipients of Corneal Grafts IOVS j April 2016 j Vol. 57 j No. 4 j 1581
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/Journals/IOVS/935164/ on 04/21/2016
The inflammatory cell infiltrate also correlated with the
clinical findings. In WT mice that were HSV infected and
grafted with syn- or allograft, there was a heavy corneal cellular
infiltration of CD11bþ and Gr1þ cells with few F4/80þ cells
(Figs. 4a–f) and no colocalization of Gr1 and F4/80 staining
(Figs. 4g–i), suggesting a predominantly neutrophilic infiltrate.
Typical multilobed nuclei of Gr1þ polymorphic infiltrating cells
were also observed (Fig. 4h, arrow). Similar findings of
inflammatory cell infiltration in HSV-infected and grafted eyes
with syngeneic corneas were found, while CD4þ T cells were
not detected in HSV-infected corneas which had received
either a syn- or allograft (data not shown). In contrast, corneas
from CD4/ HSV-infected allografted mice exhibited minimal
infiltration of inflammatory cells, which was mainly CD11bþ
Gr1 (presumed macrophages) with a few CD11bþ Gr1þ
(presumed neutrophils) observed near the sutures (black
arrows, Fig. 5a) unlike rejecting allografts in HSV-1–infected
CD4/ recipients that were reconstituted with CD4þ T cells,
which had a heavy graft CD11bþ Gr1 and CD11bþ Gr1þ cell
infiltrate (Fig. 5b).
Evidence of Virus Reactivation in HSV-Infected WT
BALB/c Mice Following Corneal Graft
We next explored the possibility that latent HSV reactivation
was the cause of graft failure in HSK recipients. Periocular
herpetic vesicles accompany HSV keratitis during the early
stages of infection, but clear after 2 to 3 weeks and do not
normally recur.23 In WT mice grafted 42 days post infection
(i.e., long after viral clearance), 10% of allografted mice were
observed to develop periocular herpetic vesicles at various
times post grafting (2–22 days post graft, equal to 44–66 dpi;
Fig. 6a). In contrast periocular vesicles were not observed in
syngeneic grafted mice (Fig. 6b). Peak incidence for vesicle
occurrence in allografted mice was seven days post grafting (4/
17 mice), some mice having more than one recurrence (Fig.
6b).
We also sought evidence of viral reactivation/shedding in
tears, cultured TG explants and in samples of corneal tissue (by
RT-PCR [data not shown] and by PCR techniques, see Methods)
from WT HSK recipient mice after grafting. Herpes simplex
virus negative control samples were prepared from na¨ıve, not
infected BALB/c animals grafted with B6 cornea. No evidence
for viral shedding in tear samples was observed nor was virus
cultured from TG explants directly ex vivo (data not shown).
Herpes simplex virus type 1 gH RNA (HSV-1 glycoprotein H)
was detected in TG samples by PCR from HSV-infected,
allografted mice at days 3 and 7 post grafting. In contrast, no
HSV gH RNA was detected at any time point from samples of
corneal grafts (Fig. 6c). Both TG and corneal grafts from not
infected, control group were negative for gH PCR product.
FIGURE 4. Infiltration of macrophages and neutrophils into corneal grafts in WT HSK mice. Corneal allografts stained with Gr1 and CD11b
antibodies in early phase post corneal graft, day 3 (a–e) and day 7 (f) in HSK recipients show massive neutrophil (Gr1þ) and macrophage (CD11bþ)
infiltration in the recipient cornea as well as in the donor corneal graft and anterior chamber of the eye. Dual staining of confocal microscopy images
of day 7 grafts (g–i) show that majority of these cells are neutrophils (Gr1þCD11bþF4/80) and macrophages (Gr1CD11bþ); white arrow indicating
multilobed nucleus at day 7 post grafting (h). The F4/80þ cells (g, i) were infrequently observed cells in the inflammatory cell infiltrate and did not
colocalize with Gr1þcells (g). Scale bars: 50 lm.
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FIGURE 5. Immune cell infiltration into corneal grafts of HSV-infected hosts. Ten days after HSV-1 corneal infection, CD4/ mice received an
allogeneic corneal transplant without CD4 T-cell transfer (a) or with adoptive transfer of na¨ıve WT BALB/c CD4 T cells (b). Transplanted corneas
were excised and stained with DAPI (blue), CD11b (green), and Gr1 (red) prior to imaging with confocal microscopy. Representative montages
were acquired with320 objective. Full-thickness reconstructions are shown in the xy top and xz (middle) planes. The xz image is displayed with
the corneal epithelium facing up and the endothelial side facing down. The arrow indicates the border between the host (left) and graft. The
bottom panels depict representative montages of full-thickness reconstructions acquired with a340 objective in the xy plane.
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T-Cell Responses in HSK Recipients After Grafting
Finally, we examined peripheral T-cell responses to HSV
antigen, B6 alloantigen, and to nonrelated OVA antigen in
allografted HSK recipients and compared the responses to HSV-
infected, nongrafted mice. Herpes simplex virus type 1 antigen
was prepared from protein extracts of HSV-infected VERO cells
while B6 alloantigen was prepared from C57BL/6 spleen
homogenates. Lymphocyte (predominantly T cell) proliferative
responses from individual eye-DLN from each mouse were
assessed by [3H]-thymidine incorporation (see Methods). A
variable but robust T-cell response in eye-draining (subman-
dibular) lymph node (DLN) cells from nongrafted HSK mice
was detected 3 dpi, which persisted for several weeks (the
duration of the experiment; Fig. 7a). A strong anti-HSV
lymphocyte T-cell response was detected in allografted HSK
mice (7 days post transplant, i.e., 49 dpi) of similar magnitude
to the anti-HSV response 5 dpi in nongrafted HSK mice (Fig.
7b, middle panel). Importantly, DLN cells from allografted HSK
recipients failed to respond in the absence of HSV antigen (Fig.
7b, top panel) while the response to alloantigen was minimal
(Fig. 7b, bottom panel). Syngeneic mice produced a low but
variable anti-HSV T-cell response (P ¼ 0.11).
DISCUSSION
Herpes simplex virus type 1 infection of the eye is common.
The most recent epidemiologic evidence from the Unites States
documents an overall incidence of 6.8% per 100,000 person
years and a prevalence of 5.7% with an increasing prevalence
with age (18.8% in people > 75 years). These data are not
greatly dissimilar from data in previous studies dating back
more than 50 years.25 The most common form of ocular
disease in this study was epithelial keratitis (72%) while stromal
keratitis (HSK) accounted for 36% of cases overall.25 Stromal
keratitis is considered to be a significant cause of blindness and
is the most common cause of infectious corneal blindness in
the United States. Global estimates are difficult to obtain but a
recent review estimates that HSK causes serious blindness
(visual acuity <20/200) in approximately 1.5% of cases of
HSK.26 Blindness in HSK is due to corneal stromal opacification
for which the only treatment is corneal transplantation.
However, inflammation of the cornea, and particularly HSK,
constitutes a high risk for graft failure (‘‘high-risk graft’’) with
10-year survival rates as low as 50% to 60%.27
The increased risk of graft failure/rejection in HSK
recipients has been attributed to corneal vascularization of
the host bed.11,27–29 Stromal keratitis not only induces blood
vessel growth but also induces extensive lymphangiogenesis,30
which provides the transit for a robust anti-HSV T-cell response
initially generated in the eye draining lymph node (Fig. 7).31
Neovascularization from any cause is considered to be an
independent risk factor for corneal allograft rejection27 and this
has been experimentally validated in the commonly used
suture-induced neovascularization ‘‘high-risk’’ graft rejection
model.18,19 Syngeneic grafts in the suture-injury model are not
at risk of rejection and survive normally. The data in the
present study confirm the strong association of allograft
rejection with neovascularization (Fig. 1). In addition, in the
HSK model reported here, graft ‘‘rejection’’ extended to
syngeneic grafts and was more akin to graft ‘‘failure,’’ because
it developed very early after grafting (3 days) and was
associated with a heavy inflammatory myeloid cell infiltrate
(Figs. 1, 4).
Herpetic stromal keratitis is a well-recognized cause of graft
failure in humans in which HSV antigen has been detected in
the stroma and even in the endothelial cells.13,32 However, the
presence of subclinical inflammation independently of neovas-
cularization has been identified in HSK as a significant
predictor of graft failure in humans.9,33 In the present
experimental study, we also observed that after HSV infection
there was an accelerated tempo of allograft rejection that
FIGURE 6. Detection of HSV-1 reactivation. A corneal allograft was placed on a recipient bed with previous HSK but no vascularization at the time
of grafting. At the time of grafting the recipient mouse showed no signs of periocular herpetic skin disease. (a) An obvious periocular vesicular skin
lesion appeared 7 days after placement of the allograft although the graft remains clear at this early time post grafting. (b) Table showing the
incidence of reactivation of periocular HSV vesicles in HSK recipients (allo- and syngrafts). (c) DNA detection of gH protein in corneal tissue and TG
in noninfected and HSV-infected (infected with HSV 42 days previously) recipients of corneal allografts. Herpes simplex virus gH bands were
detected only in HSV-infected animals and only in the TG, but not in the cornea of transplanted mice. Controls for the TG upper panel are as
follows: (1) HSVþTG 7 dpi, (2) dH20, (3) HSVþVero cell extract, (4)/(5) HSVþcorneas 3 dpi, (6) ladder. Controls for themiddle cornea panel are as
follows: (1) dH20, (2) HSVþ TG 7 dpi, (3) HSVþ Vero cell extract, (4)/(5) HSVþ corneas 3 dpi, (6) ladder.
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occurred in mice in which neovascularization and opacity
were absent (Fig. 2a). This effect was lost in CD4þ T cell–
deficient mice and could be restored when the mice were
reconstituted with na¨ıve CD4þ T cells, although at a slightly
slower tempo than WT mice (Fig. 2b). In contrast, most
syngeneic grafts were accepted in CD4/ mice reconstituted
with na¨ıve T cells (Fig. 2c). This indicates that the transferred T
cells might require some degree of specificity to induce graft
rejection or failure. In the case of HSK-allografts adoptive
transfer of na¨ıve host T cells is sufficient to initiate graft
rejection. However, in HSK-syngrafts allospecificity is not
operational and T-cell mediated graft rejection or failure would
probably require adoptive transfer of anti-HSV specific T cells
(Figs. 2b, 2c).
In fact, the data in this study provide evidence for a
significant anti-HSV response in both HSK-allografts and HSK-
syngrafts in that the graft failure/rejection data correlated with
the systemic anti-HSV response. Following HSV infection of the
cornea, a robust anti-HSV T-cell response developed, which
was variable but persisted for the duration of the experiment
(42 days). A similar, strong response was observed in the DLN
of allografted HSK mice and at a significantly lower level in
syngrafted HSK mice. In both cases, the anti-HSV response was
considerably stronger than the allospecific T-cell response in
allografted mice (Fig. 7). A T-cell response is necessary for the
development of HSK,34 and CD4 T cells are particularly
important for induction of HSK in mice by the RE strain of
HSV.35 The data in this study also implicate the CD4 T-cell
response in allograft rejection in HSK mice and point toward a
specific anti-HSV response as a major contributor to graft
failure/rejection. Herpes simplex virus type 1–specific CD4þ T
cells have been detected in HSV-infected human corneas36 and
HSV antigens are present in recipient corneal buttons from
patients undergoing corneal graft surgery.37 Given that HSV-
infected corneas appear to harbor persistent chronic infection9
it is likely that at least part of this cell infiltrate will include
HSV-specific resident effector memory T cells.
The question then arises: does graft in HSK induce
activation of latent virus from the TG or does the surgical
procedure itself activate locally resident HSV-specific resident
effector memory T cells in a bystander fashion? In the present
study we have detected viral DNA in TG but not in the corneal
graft in HSK recipients. However, given that nerve endings to
the graft will be severed during the procedure and are not
likely to have regenerated in the immediate post graft period,
anterograde passage of reactivated HSV may not be possible
and so it is not unexpected that HSV DNA was not detected in
the graft. However, we noted that there was a significant
induction of periocular skin vesicles in allografted mice, which
we interpret as reactivation of HSV in the intact skin branches
of the TG neurones. Furthermore, there was a strong anti-HSV
T-cell response associated with allografting HSK recipients, less
so in syngeneic recipients, which would be consistent with
viral reactivation and increased levels of viral antigen to
activate HSV-specific effector memory T cells. In addition,
other immune cells, including neutrophils and macrophages,
heavily infiltrated rejected grafts. Infiltration of neutrophils is a
feature of HSK,37,38 further suggesting that HSV-driven
mechanisms are accelerating graft rejection.
In summary, the data in this report are consistent with the
concept that three components contribute to allograft
rejection in the HSV-1–infected corneas, preexisting activated
innate immunity (persistent inflammation and vascularization),
an HSV-1 specific CD4 T-cell response and a weak allo-
response. Syngeneic grafts appear to fail when there is a
combination of preexisting innate immune response and an
HSV-1 specific CD4 T-cell response. However, in the absence of
preexisting innate immunity both an HSV-1 CD4 T cell and an
allo-specific response are necessary for the graft to fail. These
data suggest that both the innate and the adaptive immune
FIGURE 7. Detection of anti–HSV-1 lymphocyte proliferation responses in the eye-DLN. (a) Lymphocyte proliferation from eye-DLN at different
times after infection with HSV-1. Note consistent anti-HSV response even at the time-point when clinically the cornea is healed (i.e., day 42 dpi¼
time-point of corneal grafting procedure). (b) Lymphocyte proliferation responses to HSV antigen and B6 alloantigen day 7 post corneal allo- and
syngraft (i.e.,¼ day 49 pi). The response to HSV antigen after allografting procedure (middle panel) was equal to the lymphocyte response to HSV
antigen 5 dpi in the ungrafted cornea. The difference between the allo- and syngraft response is not significant (see main text).
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responses must be controlled if corneal grafts are to survive in
patients with HSK.
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